The value of improving the productivity of the drug development process: faster times and better decisions.

Published on Jan 1, 2002in PharmacoEconomics3.705
· DOI :10.2165/00019053-200220003-00001
Joseph A. DiMasi26
Estimated H-index: 26
(Tufts University)
Objectives: This study examines the financial benefits that can accrue to drug developers from improvements in the drug development process. The effect on drug development costs from faster development, earlier decisions on project failures, and higher approval success rates are quantified.
  • References (13)
  • Citations (173)
📖 Papers frequently viewed together
3,045 Citations
2,744 Citations
359 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
#1Joseph A. DiMasi (Tufts Center for the Study of Drug Development)H-Index: 26
#2Ronald W. Hansen (UR: University of Rochester)H-Index: 7
Last. Henry G Grabowski (Duke University)H-Index: 39
view all 3 authors...
The research and development costs of 68 randomly selected new drugs were obtained from a survey of 10 pharmaceutical firms. These data were used to estimate the average pre-tax cost of new drug development. The costs of compounds abandoned during testing were linked to the costs of compounds that obtained marketing approval. The estimated average out-of-pocket cost per new drug is US$ 403 million (2000 dollars). Capitalizing out-of-pocket costs to the point of marketing approval at a real disco...
3,045 CitationsSource
N A FRIDAY EVENING AROUND dinnertime, Neil Bartlett, working all alone in his laboratory, made the discovery of a lifetime. His discovery, which shattered the textbook axiom that the noble gases were inert and could not be induced to react with other chemical species, grew out of earlier work he did with graduate student Derek H. Lohmann. They established that the gas platinum hexafluoride (PtF6) has such an extraordinarily high electron affinity that it can oxidize molecular oxygen to form the ...
8 CitationsSource
#1Karen J. WatkinsH-Index: 1
12 CitationsSource
#1Henry G Grabowski (Duke University)H-Index: 39
#2John M Vernon (Duke University)H-Index: 19
Last. Joseph A. DiMasi (Tufts University)H-Index: 26
view all 3 authors...
Background: Previously published research by the authors found that returns on research and development (RD indications that RD new market strategies of major firms aimed at simultaneous launches across world markets; and the increased attention focused on the pharmaceutical industry in the political arena.
221 CitationsSource
#1Joseph A. DiMasi (Tufts Center for the Study of Drug Development)H-Index: 26
183 CitationsSource
#1Joseph A. DiMasi (Tufts Center for the Study of Drug Development)H-Index: 26
359 CitationsSource
#1Christopher-Paul Milne (Tufts Center for the Study of Drug Development)H-Index: 11
#2Elaine Bergman (Tufts Center for the Study of Drug Development)H-Index: 1
With the passage of the Food and Drug Administration Modernization Act (FDAMA), existing programs for expedited development and approval for treatments of serious or life-threatening diseases were codified and consolidated under the administrative rubric of fast track product designation. The four basic programs available with fast track designation have been categorized by FDA as consisting of meetings, written correspondence, review programs, and dispute resolution. Despite some early skeptici...
11 CitationsSource
#1Joseph A. DiMasi (Tufts University)H-Index: 26
#2Erol Caglarcan (Johnson & Johnson)H-Index: 1
Last. Maria Wood-Armany (Tufts University)H-Index: 1
view all 3 authors...
Objectives: This study examines the organisational structure of pharmacoeconomics departments in major pharmaceutical and biotechnology companies, the impediments to optimal use of pharmacoeconomic evaluations by companies and the integration of pharmacoeconomic analysis with research and development decision making. Data and Methods: The heads of the pharmacoeconomics departments of 40 companies were surveyed on the structure of pharmacoeconomics departments in their companies, the roles that p...
53 CitationsSource
#1Joseph A. DiMasi (Tufts Center for the Study of Drug Development)H-Index: 26
This study examines what is generally regarded to be the most important measure of innovation in the pharmaceutical industry—the extent to which new drugs are developed and marketed by pharmaceutical firms. Pharmaceutical industry output, as measured by new chemical entity (NCE) approvals in the United States since the 1962 Amendments to the Federal Food, Drug, and Cosmetic Act of 1938, is examined at the firm level. This long-term historical perspective permits us to observe the extent to which...
58 CitationsSource
#1Kenneth I. Kaitin (Tufts Center for the Study of Drug Development)H-Index: 24
#2Joseph A. DiMasi (Tufts Center for the Study of Drug Development)H-Index: 26
The Prescription Drug User Fee Act of 1992 (PDUFA) is credited with the dramatic reduction in new drug approval times seen since 1993. Despite the faster approval times, however, the total time required for new drugs to reach the marketplace had not changed appreciably. With passage of the FDA Modernization Act of 1997 (FDAMA), the United States Food and Drug Administration (FDA) expanded its focus from shortening the regulatory review phase to helping drug developers reduce lengthy clinical dev...
36 CitationsSource
Cited By173
The subject of this paper is pharmaceutical companies and the risk factors that occur in the distribution of drugs. The paper will present guidelines for the risk management of changes in the environment of pharmaceutical distribution channels. To identify, analyse, and prioritise risks, we used a systematic literature review and the Delphi method. Identification and assessment of important risk factors in drug distribution channels were conducted based on opinions of experts from 10 internation...
#1Joseph A. DiMasi (Tufts Center for the Study of Drug Development)H-Index: 26
#2Michael Wilkinson (Tufts Center for the Study of Drug Development)H-Index: 2
PURPOSE Faster drug development times get new therapies to patients sooner and financially benefit drug developers by shortening the time between investment and returns and increasing the time on the market with intellectual property protection. The result is enhanced incentives to innovate. We provide a real-world example of the financial gains from quicker development using recent estimates of drug development costs, returns, and estimates of time reductions from an alternative early-stage dru...
#1Patrice Nony (CNRS: Centre national de la recherche scientifique)H-Index: 19
#1Patrice NonyH-Index: 1
Last. Catherine Cornu (French Institute of Health and Medical Research)H-Index: 23
view all 3 authors...
Based on the 'European Child-Rare-Euro-Simulation' (CRESim) project, this article proposes a generalizable strategy utilizing datasets analysis in combination with modeling and simulation, in order to optimize the clinical drug development applied in the field of rare diseases. The global process includes: (i) the simulation of a realistic virtual population of patients (modeled from a real dataset of patients), (ii) the modeling of disease pathophysiological components and of pharmacokinetic-ph...
#1Nandini Dhiman (Swinburne University of Technology)H-Index: 2
#2Peter Kingshott (Swinburne University of Technology)H-Index: 41
Last. Subha Narayan Rath (IITH: Indian Institute of Technology, Hyderabad)H-Index: 15
view all 5 authors...
There is an increasing need for advanced and inexpensive preclinical models to accelerate the development of anticancer drugs. While costly animal models fail to predict human clinical outcomes, in vitro models such as microfluidic chips (‘tumor-on-chip’) are showing tremendous promise at predicting and providing meaningful preclinical drug screening outcomes. Research on ‘tumor-on-chips’ has grown enormously worldwide and is being widely accepted by pharmaceutical companies as a drug developmen...
7 CitationsSource
#1Xuhua Han (CSU: Central South University)
#2Fang Li (CSU: Central South University)
Last. Zeneng Cheng (CSU: Central South University)H-Index: 11
view all 6 authors...
: Mefunidone (MFD), a novel derivation of pirfenidone (PFD), exhibits promising anti-renal fibrosis activity. To avoid early development failures and attrition in clinical phase 1, an evaluation of the preclinical pharmacokinetic (PK) properties of MFD was conducted in this study. The absolute bioavailability was evaluated in Sprague Dawley rats and cynomolgus monkeys, who received an intragastric or intravenous administration at the dose of 31.25 mg/kg and 10 mg/kg, respectively. Tissue distrib...
#1Joanne Neale ('KCL': King's College London)H-Index: 30
#2Charlotte N. E. Tompkins ('KCL': King's College London)H-Index: 15
Last. John Strang ('KCL': King's College London)H-Index: 64
view all 3 authors...
Background Options for opioid agonist therapy (OAT) are expanding with the development of prolonged-release (also known as extended-release) 1-week, 1-month, and 6-month formulations of buprenorphine. There is an assumption that patients will welcome these new treatments and medication adherence will correspondingly increase. However, there has been little research exploring patients’ views of prolonged-release buprenorphine. This paper aims to understand which durations patients prefer and why,...
6 CitationsSource
#1S. Lakshmana Prabu (Anna University)H-Index: 5
1 CitationsSource
#1Thomas Walter (RWTH Aachen University)H-Index: 2
#2Christoph Ihl (RWTH Aachen University)H-Index: 9
Last. Malte Brettel (RWTH Aachen University)H-Index: 31
view all 4 authors...
What motivates university scientists to identify practical applications for their research results and consider having them patent-protected? A wealth of research points towards a complex blend of factors, including organizational antecedents, social norms and personal-level expectations. Few studies, however, have attempted to investigate the effect of concrete incentives from the perspective of individual scientists’ decision-making. In this paper, we operationalize the propensity to patent an...
9 CitationsSource
#1Qi Chen (Imperial College London)H-Index: 1
#2Remigijus Paulavičius (Imperial College London)H-Index: 10
Last. Salvador García-Muñoz (Eli Lilly and Company)H-Index: 16
view all 4 authors...
4 CitationsSource